40 patients with benign upper digestive tract disease were divided into 3 groups according to their own will.

Patients in the 1st treatment group were treated orally with MEBO Gastrointestinal Capsule alone, patients in the 2nd treatment group were treated orally with MEBO Gastrointestinal Capsule plus “standard 3 combination” therapy and patients in control group were treated with “standard 3 combination” therapy alone. 

Gastroscopic examination was done before and after treatment, to observe the changes in the lesion area. 

Result：

Most of the patients in the 3 groups had stomach and duodenal ulcers, accounted for 64.4%. 

The curative rate in the 1st treatment group was 78.9%, in the 2nd treatment group was 75.0% and in the control group 70.0%. The difference among the 3 groups had no statistical significance. 

Conclusion：

The short-term efficacy of MEBO Gastrointestinal Capsule in treating benign upper digestive tract lesion examined by endoscope is up to the level of the “standard 3 combination” therapy.

Full Report:

Clinical research on MEBO Gastrointestinal Capsule for treating benign upper digestive tract disease